E-viri
Recenzirano
Odprti dostop
-
Kaumanns, Anna; König, David; Hojski, Aljaz; Cattaneo, Marco; Chirindel, Alin; Wiese, Mark; Tamm, Michael; Lardinois, Didier; Rothschild, Sacha I.
Lung cancer, November 2022, 2022-11-00, 20221101, Letnik: 173Journal Article
•In this real-world analysis of 205 patients with resected stage I-III NSCLC rate for recurrence and secondary primary lung cancer was 22 % and 8 %, respectively.•83 % of recurrences, and 65 % of SPLC were detected on FDG-PET/CT that was done after 6, 12 and 24 months after resection.•In this patient cohort second curatively intended treatment was possible in 37% of pts with recurrence and 100% with SPLC.•Recurrence was identified in more than 80% of all cases in one of the three FDG-PET/CTs during the first two years after resection.•A postoperative surveillance strategy with regular FDG-PET/CT scans is able to identify curatively treatable recurrences with high percentage. The optimal surveillance strategy in patients with resected non-small cell lung cancer (NSCLC) is unknown. Early detection of recurrences by follow-up imaging might improve survival and whole-body 18F-FDG-PET/CT might be the optimal imaging modality given its high accuracy in preoperative staging. Data from a single-center cohort of 205 patients with resected stage I-III NSCLC and FDG-PET/CT surveillance was retrospectively collected. Patients had preoperative FDG-positive tumors and FDG-PET/CT at 6, 12, 24 months, chest CT at 18 months. Thereafter, annual chest CT was performed for stage I-II, annual FDG-PET/CT for stage III. With a median follow-up of 26.3 months (range, 4.1–60.6), the rate for recurrence and secondary primary lung cancer (SPLC) was 22 % and 8 %, respectively. Associated symptoms were present in 48 % (recurrence) and 18 % (SPLC) of patients. Overall, 83 % of recurrences, and 65 % of SPLC were detected on FDG-PET/CT. 82 % of recurrences were detected in one of the first two follow-up PET/CT scans. Second curatively intended treatment (SCIT) was possible in 37 % of patients with recurrence and 100 % with SPLC. The 2-year recurrence-free survival rate after SCIT for recurrence was 53 % 95 %CI; 31–91 %. Non-malignant FDG-positive findings occurred in 25 % of patients (71 % possible infections). In our cohort of patients, more than 80% of all recurrences were identified in one of the three FDG-PET/CTs performed as part of our imaging protocol during the first two years after resection. Nearly all patients with non-distant recurrence qualified for a SCIT. Further studies are needed to identify patients who might benefit from an even more intensive surveillance strategy.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.